On Thursday, drugmaker Sanofi announced that it is joining Eli Lily and Novo Nordisk in reducing the price of insulin. The three companies, which dominate the global insulin market, were recently sued by the state of California, alleging they illegally drive up the cost of the drug.
"It seemed like only a matter of time before Sanofi also made changes," said Stacie Dusetzina, a health policy professor at Vanderbilt University Medical Center. "You don't want to be a standout."
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
